Complete JHO manuscript draft v3 created for journal submission
Source type:
obs· Harvested: 2026-05-04 · Original date: 2026-05-04T01:52:34.970Z Metadata:{"project":"oncology-fih-research/oncology-fih-research","type":"feature","obs_id":65272}
obs/65272 · feature · 2026-05-04T01:52:34.970Z
Complete JHO manuscript draft v3 created for journal submission
A complete, journal-ready manuscript was created documenting the ClinicalTrials.gov early-phase oncology landscape analysis. The manuscript follows academic publication standards with full IMRAD structure (Introduction/Methods/Results/Discussion), STROBE-compliant observational reporting, and complete front matter including author affiliations, keywords, and corresponding author information. The analysis narrative integrates all previously generated tables and figures, documents key findings including the rise of industry sponsorship to 79.6%, China’s emergence as the #2 country with 1667 participations, site concentration around MD Anderson (1149 trials), and modality diversification beyond checkpoint inhibitors into ADCs, bispecifics, KRAS/RAS agents, and PD-1/VEGF bispecifics. The Discussion section provides context on FIH-enrichment interpretation, industry dominance implications, geographic redistribution, modality convergence, and site concentration limits, while acknowledging comprehensive limitations. The manuscript cites real-world examples like Merck’s LM-299 license and BioNTech’s BNT327 partnership, grounds all claims in the reproducible data freeze, and includes full Declarations required for journal submission.
Concepts: [“what-changed”,“how-it-works”,“why-it-exists”]
Facts: [“Manuscript draft-v3-jho.md contains full IMRAD structure: Abstract, Background, Methods, Results, Discussion, Conclusions, Declarations, References”,“Documents analysis of 9869 unique ClinicalTrials.gov trials from 21096 retrieved records with 1004 strict FIH and 4883 FIH-enriched subset”,“Includes 5 embedded tables covering sponsor/era trends, country distribution, site ranking, and modality evolution by era”,“References 25 peer-reviewed publications and cites specific focus programs NCT06650566 (Merck LM-299) and BNT327/pumitamig (BioNTech)”,“Ready for submission with complete Declarations section, supplementary file references, figure legends, and data availability statement”]
[← 回 Alfred Brain Hub]